Mamazhakypov Argen, Maripov Abdirashit, Sarybaev Akpay S, Schermuly Ralph Theo, Sydykov Akylbek
Department of Internal Medicine, Excellence Cluster Cardio-Pulmonary Institute (CPI), Member of the German Center for Lung Research (DZL), Justus Liebig University of Giessen, 35392 Giessen, Germany.
Department of Mountain and Sleep Medicine and Pulmonary Hypertension, National Center of Cardiology and Internal Medicine, Bishkek 720040, Kyrgyzstan.
Biomedicines. 2023 May 7;11(5):1385. doi: 10.3390/biomedicines11051385.
Pulmonary hypertension (PH) is a pathological condition with multifactorial etiology, which is characterized by elevated pulmonary arterial pressure and pulmonary vascular remodeling. The underlying pathogenetic mechanisms remain poorly understood. Accumulating clinical evidence suggests that circulating osteopontin may serve as a biomarker of PH progression, severity, and prognosis, as well as an indicator of maladaptive right ventricular remodeling and dysfunction. Moreover, preclinical studies in rodent models have implicated osteopontin in PH pathogenesis. Osteopontin modulates a plethora of cellular processes within the pulmonary vasculature, including cell proliferation, migration, apoptosis, extracellular matrix synthesis, and inflammation via binding to various receptors such as integrins and CD44. In this article, we provide a comprehensive overview of the current understanding of osteopontin regulation and its impact on pulmonary vascular remodeling, as well as consider research issues required for the development of therapeutics targeting osteopontin as a potential strategy for the management of PH.
肺动脉高压（PH）是一种病因多因素的病理状态，其特征为肺动脉压力升高和肺血管重塑。其潜在的发病机制仍知之甚少。越来越多的临床证据表明，循环骨桥蛋白可能作为PH进展、严重程度和预后的生物标志物，以及适应性右心室重塑和功能障碍的指标。此外，在啮齿动物模型中的临床前研究表明骨桥蛋白与PH发病机制有关。骨桥蛋白通过与整合素和CD44等各种受体结合，调节肺血管内大量的细胞过程，包括细胞增殖、迁移、凋亡、细胞外基质合成和炎症。在本文中，我们全面概述了目前对骨桥蛋白调节及其对肺血管重塑影响的理解，并考虑了将靶向骨桥蛋白的治疗方法作为PH管理潜在策略开发所需的研究问题。
